KRP 297 (Synonyms: MK-767) |
| Katalog-Nr.GC48521 |
KRP 297 ist ein PPARα- und PPARγ-Agonist, der potenziell zur Behandlung von Typ-2-Diabetes und Dyslipidämie eingesetzt werden kann.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 213252-19-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
KRP 927 is a thiazolidinedione dual agonist of PPARα and PPARγ (EC50s = 149 and 83 nM, respectively, in transactivation assays).1 It decreases hyperglycemia and hyperinsulinemia in ob/ob mice in a dose-dependent manner. KRP 927 (10 or 30 mg/kg) reduces serum total cholesterol and triglyceride levels in hamsters.
1.Doebber, T.W., Kelly, L.J., Zhou, G., et al.MK-0767, a novel dual PPARα/γ agonist, displays robust antihyperglycemic and hypolipidemic activitiesBiochem. Biophys. Res. Commun.318(2)323-328(2004)
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *